Expanding the DED Toolkit: Cold-Sensitive Approaches to Tear Regulation

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Janelle L. Davison, OD; Cecelia Koetting, OD, FAAO, DipABO; and Cory J. Lappin, OD, MS, FAAO; discuss neuromodulation as a treatment modality for dry eye disease, focusing on a novel thermoregulatory therapy.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Describe the neural network that monitors the ocular surface environment and regulates tear secretion
• Assess the mechanisms of action of neuromodulation therapeutics in dry eye disease (DED)
• Evaluate current and emerging therapeutics for DED
• Identify clinical applications and patient selection for neuromodulation therapies in DED

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from Alcon Vision, Inc.

Faculty:

Janelle L. Davison, OD

Owner and Clinical Director
Brilliant Eyes Vision Center
Visionary Dry Eye Institute
Smyrna, GA

Disclosures: Janelle L. Davison, OD, has no relevant financial relationships with ineligible companies.

Cecelia Koetting, OD, FAAO, DipABO

Assistant Professor
Department of Ophthalmology
University of Colorado School of Medicine
Denver, CO

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie/Allergan, Alcon Inc, Bausch + Lomb, Dompé, Harrow, Movu, Myze, Orasis Pharmaceuticals, Tarsus Pharmaceuticals, Topcon, Viatris Inc, Visus; Grant/Research Funding: Kala Bio

Cory J. Lappin, OD, MS, FAAO

Founder
The Dry Eye Center of Ohio
Cincinnati, OH

Disclosures: Advisory Board, Consultant, Speaker: Alcon Inc; Barti; Bausch + Lomb; Bruder Healthcare and M&S Technologies (Hilco Vision); CSI Dry Eye Software; Dompé Pharmaceuticals; Eyederm; Eyenovia; Harrow, Inc; Lumenis; Myze; Nordic Pharma; Norwood Device & Diagnostics; NuLids; Ocubio; PRN Vision Group; Rinsada; SCOPE Health Inc; Sight Sciences; Tarsus Pharmaceuticals, Inc; TearRestore Inc; Viatris Inc (Oyster Point Pharma); Vital Tears LLC; Investment: Barti, Myze, NuLids; Ownership Stake: Eyederm; Executive Team Member: Myze; Medical Director: Norwood Device & Diagnostics

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including further data on neuromodulating dry eye therapies, go to https://www.gotoper.com/boston25optometry-ded-activity.

Release Date

January 30, 2026

Expiration Date

January 30, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.